Details of the Drug Combinations

General Information of This Drug (ID: DMBMUWZ)

• Drug Name: Emtricitabine (DMBMUWZ)
• Synonyms: Coviracil; DOTFC; Emtriva; RCV; Racivir; BW 1592; BW 524W91; BW524W91; BW-524W91; Coviracil (TN); Coviracil(TM); DRG-0208; Emtriva(TM); Emtricitabine (JAN/USAN/INN); Beta-L-2',3'-dideoxy-5-fluoro-3'-thiacytidine; Beta-L-(-)-(2R,5S)-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-(2R,5S)-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine; (-)-.beta.-L-FTC; (-)-2',3'-Dideoxy-5-fluoro-3'-thiacytidine; (-)-2'-Deoxy-5-fluoro-3'-thiacytidine; (-)-FTC; (-)-beta-2',3'-dideoxy-5-fluoro-3'-thiacytidine; (-)-cis-4-amino-5-fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one; (2R-cis)-4-Amino-5-fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)-2(1H)-pyrimidinone; 1-(2-(Hydroxymethyl)oxathiolan-5-yl)-5-fluorocytosine; 2',3',5-FTC; 2',3'-Dideoxy-5-fluoro-3'-thiacytidine; 2'-Deoxy-5-fluoro-3'-oxa-4'-thiocytidine; 2'-Deoxy-5-fluoro-3'-thiacytidine; 2-FTC; 3'-Thia-2'.3'-dideoxy-5-fluorocytidine; 4-Amino-5-fluoro-1-[(2R,5S)-(hydroxymethyl)-1,3-oxathiolan-5-yl]-2(1H)-pyrimidinone; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2(1H)-one; 4-amino-5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one; 5-Fluoro-1-((2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-Fluoro-1-(2-(hydroxymethyl)-1,3-oxathiolan-5-yl)cytosine; 5-fluoro-1-[(2R,5S)-2-(hydroxymethyl)[1,3]oxathiolan-5-yl]cytosine; 524W91; FTC

Indication

Hepatitis virus infection; ICD 11: 1E50-1E51; Status: Approved [1]; Human immunodeficiency virus infection; ICD 11: 1C62; Status: Approved [1]; Hepatitis B virus infection; ICD 11: 1E51.0; Status: Phase 3 [2]

• Therapeutic Class: Anti-HIV Agents
• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Emtricitabine + Idarubicin	DCJNT9D	Idarubicin	Glioblastoma? (Cell Line: T98G)	[3]

22 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Emtricitabine + Lopinavir	DC36BFO	Lopinavir	Acute HIV Infection	[4]
Emtricitabine + Darunavir	DC0YJIS	Darunavir	HIV Infections	[5]
Emtricitabine + Lopinavir	DCKSN07	Lopinavir	Acute HIV Infection	[4]
Emtricitabine + Maraviroc	DCPOUHM	Maraviroc	HIV Infection	[6]
Emtricitabine + Tenofovir alafenamide	DC2A9FF	Tenofovir alafenamide	Human immunodeficiency virus-1 infection	[7]
Emtricitabine + Tenofovir alafenamide	DCJIOQC	Tenofovir alafenamide	Human immunodeficiency virus-1 infection	[7]
Emtricitabine + Tenofovir alafenamide	DCA6JSD	Tenofovir alafenamide	HIV	[8]
Tenofovir + Emtricitabine	DC4VA0W	Tenofovir	Acute HIV Infection	[9]
Tenofovir + Emtricitabine	DC21DGG	Tenofovir	HIV/AIDS	[10]
Tenofovir disoproxil + Emtricitabine	DC1OKMA	Tenofovir disoproxil	Acute HIV Infection	[11]
Tenofovir disoproxil + Emtricitabine	DCSMP7W	Tenofovir disoproxil	HIV Infection	[6]
Tenofovir disoproxil + Emtricitabine	DCEVAH6	Tenofovir disoproxil	HIV	[8]
Emtricitabine + Raltegravir	DCRSKBT	Raltegravir	Primary Biliary Cholangitis	[12]
Tenofovir + Emtricitabine	DC2KNZU	Tenofovir	Infection, Human Immunodeficiency Virus	[13]
Emtricitabine + Tenofovir alafenamide	DCZ4OHF	Tenofovir alafenamide	HIV	[14]
Tenofovir disoproxil + Emtricitabine	DC688W3	Tenofovir disoproxil	Human Immunodeficiency Virus-type 1 Infection	[15]
Tenofovir disoproxil + Emtricitabine	DC8CXAS	Tenofovir disoproxil	Human Immunodeficiency Virus-type 1 Infection	[15]
Emtricitabine + Darunavir	DCDM84V	Darunavir	HIV	[16]
Emtricitabine + Atazanavir	DCG0IYQ	Atazanavir	HIV	[16]
Emtricitabine + Didanosine	DCN2MPA	Didanosine	HIV Infections	[17]
Tenofovir + Emtricitabine	DC0E91Q	Tenofovir	HIV-1-infection	[18]
Tenofovir + Emtricitabine	DCSIUUP	Tenofovir	HIV	[19]

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Cobicistat + Emtricitabine	DCZW32N	Cobicistat	Human immunodeficiency virus infection; Human immunodeficiency virus-1 infection	[20]

References

• [1] Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
• [2] Clinical pipeline report, company report or official report of Gilead (2011).
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT01154673) Effects of Intensive cART During Acute/Early HIV Infection
• [5] ClinicalTrials.gov (NCT00525733) Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Nave Subjects (ADARC 2007-01)
• [6] ClinicalTrials.gov (NCT01505114) Evaluating the Safety and Tolerability of Antiretroviral Drug Regimens Used as Pre-Exposure Prophylaxis to Prevent HIV Infection in At-Risk Men Who Have Sex With Men and in At-Risk Women
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] ClinicalTrials.gov (NCT02904369) PK and PD Study of Oral F/TAF for HIV Prevention
• [9] ClinicalTrials.gov (NCT02475915) Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV Infection
• [10] ClinicalTrials.gov (NCT03917420) Quantification of Estradiol's Impact on Nucleotides in Cellular Populations of the Lower GI Tract
• [11] ClinicalTrials.gov (NCT00734344) Pilot Study of Raltegravir/Truvada Versus Efavirenz/Truvada for Adults With Acute IV-1 Infection
• [12] ClinicalTrials.gov (NCT03954327) Combination Antiretroviral Therapy (cART) for PBC
• [13] ClinicalTrials.gov (NCT01803074) Study to Evaluate a HIV Drug for the Treatment of HIV Infection
• [14] ClinicalTrials.gov (NCT05979311) A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
• [15] ClinicalTrials.gov (NCT01709084) A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
• [16] ClinicalTrials.gov (NCT00757783) Changes in Triglyceride and Other Lipids (Levels of Fats Found in Blood) When Taking Darunavir Compared to Atazanavir in HIV-infected Patients That Have Never Received Treatment
• [17] ClinicalTrials.gov (NCT00084136) Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
• [18] ClinicalTrials.gov (NCT03360682) Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
• [19] ClinicalTrials.gov (NCT01335620) The Safety, Pharmacokinetic Profile and Efficacy of Raltegravir in HIV-infected Patients at Least 60 Years of Age
• [20] FDA Drug Development and Drug Interactions